Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy
- PMID: 18055849
- DOI: 10.1634/theoncologist.12-11-1299
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy
Abstract
Objective: Leucovorin and extracorporeal removal of methotrexate (MTX) have limited efficacy in delayed MTX elimination after high-dose methotrexate (HD-MTX) therapy. Glucarpidase (carboxypeptidase G2) cleaves MTX into nontoxic metabolites, but experience with this enzyme is limited in adult patients. We evaluated the effects of glucarpidase intervention in adult and elderly patients with delayed MTX elimination.
Patients and methods: Forty-three patients (age, 18-78 years) with MTX serum concentrations (sMTX) of 1-1,187 micromol/l received glucarpidase, leucovorin rescue guided by MTX immunoassay, and standard supportive care. MTX and MTX metabolites were quantified in serum (24 patients) and urine (8 patients) by high-performance liquid chromatography. Contributory risk factors, toxicities, and survival were recorded in all patients.
Results: Glucarpidase was well tolerated and resulted in an immediate >97% reduction in sMTX, with a 0.2%-35% urinary recovery of the total MTX dose as inactive MTX metabolites. Forty (93%) of 43 patients had normalization (n = 25) or improvement (n = 15) of their serum creatinine. Frequent grade III-IV MTX toxicities were hematological (60%) and mucositis (35%); only eight (19%) patients developed grade III-IV nephrotoxicity. Ten (23%) of 43 patients experienced fatal complications associated with HD-MTX therapy. Patients with three or more contributory risk factors for delayed MTX elimination had a significantly poorer survival than patients with fewer than three risk factors (hazard ratio, 3.64; confidence interval, 1.14-17.54).
Conclusions: Glucarpidase is well tolerated and produces a rapid inactivation of substantial amounts of MTX. However, overall results are still unsatisfactory in adult and elderly patients, suggesting that earlier recognition of delayed MTX elimination and more rapid intervention are needed.
Similar articles
-
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.Cancer. 2004 May 15;100(10):2222-32. doi: 10.1002/cncr.20255. Cancer. 2004. PMID: 15139068
-
Glucarpidase following high-dose methotrexate: update on development.Expert Opin Biol Ther. 2010 Jan;10(1):105-11. doi: 10.1517/14712590903468677. Expert Opin Biol Ther. 2010. PMID: 19925307 Review.
-
Renal dysfunction during and after high-dose methotrexate.Cancer Chemother Pharmacol. 2009 Mar;63(4):599-604. doi: 10.1007/s00280-008-0772-0. Epub 2008 May 27. Cancer Chemother Pharmacol. 2009. PMID: 18504579 Clinical Trial.
-
[The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].Therapie. 2008 Jan-Feb;63(1):19-28. doi: 10.2515/therapie:2008013. Epub 2008 Apr 4. Therapie. 2008. PMID: 18387272 French.
-
[Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].An Pediatr (Barc). 2009 Sep;71(3):230-4. doi: 10.1016/j.anpedi.2009.05.014. Epub 2009 Jul 18. An Pediatr (Barc). 2009. PMID: 19617010 Review. Spanish.
Cited by
-
High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights.Front Med (Lausanne). 2025 Mar 14;12:1495705. doi: 10.3389/fmed.2025.1495705. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40160322 Free PMC article. Review.
-
Prevention and Treatment of Acute Kidney Injury Associated with High-Dose Methotrexate.Kidney360. 2025 Mar 1;6(3):476-481. doi: 10.34067/KID.0000000725. Epub 2025 Jan 31. Kidney360. 2025. PMID: 39888669 Free PMC article. Review.
-
Considerations on the Rational Design of Covalently Conjugated Cell-Penetrating Peptides (CPPs) for Intracellular Delivery of Proteins: A Guide to CPP Selection Using Glucarpidase as the Model Cargo Molecule.Molecules. 2019 Nov 26;24(23):4318. doi: 10.3390/molecules24234318. Molecules. 2019. PMID: 31779220 Free PMC article.
-
Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.Clin J Am Soc Nephrol. 2022 Apr;17(4):602-622. doi: 10.2215/CJN.08030621. Epub 2022 Mar 2. Clin J Am Soc Nephrol. 2022. PMID: 35236714 Free PMC article.
-
Navigating methotrexate toxicity: Examining the therapeutic roles of folinic acid and glucarpidase.Br J Clin Pharmacol. 2025 Mar;91(3):628-635. doi: 10.1111/bcp.16096. Epub 2024 Jun 18. Br J Clin Pharmacol. 2025. PMID: 38889902 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical